Every KPV Question Answered, in 16 Studies

16 referenced articles

• What Is KPV? The Tripeptide From Alpha-MSH4 sources
• Nanomolar in a Dish Is Not a Dose3 sources
• The Part of the Hormone That Talks to the Receptor Is Not in KPV4 sources
• A Second Claim, With a Different Mechanism3 sources
• When the Tripeptide Is the Address, Not the Cargo3 sources
• Delete the Transporter and the Effect Disappears2 sources
• The Transporter That Explains the Tripeptide3 sources
• KPV Regulatory Status4 sources
• KPV in the Published Literature4 sources
• What the Colitis Models Reported2 sources
• Fragment Logic: KPV Against Its Parent3 sources
• KPV Storage and Handling3 sources
• KPV Chemical Identity2 sources
• KPV Structure and Physical Properties2 sources
• How KPV Is Reported to Act3 sources
• Alpha-MSH: Pigmentation and Inflammation in One Hormone3 sources

Open research questions

• Why does searching PubChem for KPV return the wrong compound?
• Is KPV's anti-inflammatory mechanism the same as alpha-MSH's?
• What does the targeted delivery literature imply about KPV's pharmacokinetics?
• How does a three-residue peptide have activity without secondary structure?
• Why is KPV harder to characterise analytically than longer peptides?
• What is the relationship between KPV and Melanotan II?

Deep dive: two functions in one hormone, and the case for splitting them

Alpha-MSH is a thirteen-residue peptide cleaved from proopiomelanocortin, and it does two things that have almost nothing to do with each other. Its core sequence engages melanocortin receptors on melanocytes and drives melanin synthesis - the activity it is named for. Separately, it carries anti-inflammatory activity that Brzoska and colleagues localised to its C-terminal end, a paper titled 'terminal signal' precisely because the finding was that the signal sits at the terminus rather than in the receptor-binding core. That is an unusually clean functional separation, and it produced two research compounds pulling in opposite directions from one parent. KPV takes the C-terminal three residues and discards the pigmentation activity. Melanotan II does the reverse - a cyclic analogue built around the receptor-binding portion to maximise exactly what KPV was designed to leave behind. Same hormone, opposite halves.

Deep dive: what happens when you shrink a molecule fivefold

Going from alpha-MSH at 1,664.9 Da to KPV at 342.43 Da is not a trim, it is a change of category. A 1,665 Da peptide is firmly a cell-surface ligand - far too large to cross a membrane passively, so whatever it does must begin at a receptor. A 342 Da tripeptide is small enough that intracellular access becomes plausible, which is why KPV's reported mechanism is described in terms of NF-kappaB signalling rather than melanocortin receptor engagement. The consequence is rarely stated: if the fragment acts inside the cell and the parent acts at its surface, then the anti-inflammatory activity of the two is not necessarily the same phenomenon, and read-across between them should run cautiously in both directions. Fragment logic assumes the fragment is the parent minus something. Here it may be the parent minus something plus a different route of access.

Deep dive: the delivery paper is the most informative thing in the literature

Xiao and colleagues published in Molecular Therapy in 2017 on delivering KPV orally using hyaluronic acid-functionalised nanoparticles targeted to inflamed intestinal tissue. Read as a result it is a delivery success. Read as a statement about the compound it is more interesting: nobody builds a targeted nanoparticle carrier for a molecule that already reaches its target. The existence of that work says the free tripeptide's arrival at inflamed tissue was the limiting problem - which follows directly from being 342 Da, highly soluble and rapidly cleared. It is the same signal that CJC-1295's DAC modification carries for growth hormone secretagogues, or that lipidation carries across the whole incretin class: when the engineering effort goes into getting a compound to stay and arrive rather than into making it more active, the pharmacokinetics were the bottleneck.

Handling checklist

• Verify identity against Lys-Pro-Val, CID 125672, at 342.43 Da
• Do not search PubChem for 'KPV' - it returns an unrelated organic acid
• Store lyophilised, cold, dry and dark
• Use low-binding consumables; a small cationic peptide adsorbs to surfaces
• Reconstitute gently down the vial wall and swirl, never shake
• Aliquot into single-use volumes to avoid freeze-thaw cycling
• Expect no disulfide or oxidation satellites - no cysteine, no methionine

Common mistakes

Searching PubChem for 'KPV' to verify a certificate

That returns CID 13294447, 2-oxo-5-phenylpentanoic acid at 192.21 Da, an unrelated compound. Search Lys-Pro-Val for CID 125672.

Treating KPV and alpha-MSH findings as interchangeable

They differ fivefold in mass and the fragment may act intracellularly where the parent cannot. Read across cautiously in both directions.

Assuming a colitis model result speaks to inflammatory bowel disease

Induced colitis in a mouse is acute and chemical; human IBD is chronic, heterogeneous and immunologically complex.

Expecting to quantify KPV by absorbance at 280 nm

There is no aromatic residue in the sequence, so there is no usable absorbance there.

Attributing unexplained low recovery to degradation

KPV is chemically robust - no cysteine, methionine or asparagine. Adsorption to glass and plastic is the more likely cause.